Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)
Primary Purpose
Multiple Sclerosis
Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
vitamin D3
Sponsored by

About this trial
This is an interventional basic science trial for Multiple Sclerosis focused on measuring Multiple Sclerosis, Regulatory T cell function, Vitamin D, Vitamin D3, 25-hydroxyvitamin D
Eligibility Criteria
Inclusion Criteria:
- Relapsing Remitting MS (Revised MCDonald criteria 2005)
- Age > 18 years
Exclusion Criteria:
- Progressive MS phenotype
- Abnormalities of vitamin D hormonal system other than low dietary intake or limited sun exposure
- Intake of drugs that influence vitamin D homeostasis other than corticosteroids
- Conditions with in increased susceptibility to hypercalcemia
- Alcohol or drug abuse
- Pregnancy or the intention to become pregnant within the study period
Sites / Locations
- Orbis Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Vitamin D3
Arm Description
Patients receive 1dd 500ug vitamin D3 for 3 months
Outcomes
Primary Outcome Measures
T cell regulation
Secondary Outcome Measures
serum 25-hydroxyvitamin D levels
calcium metabolism
Full Information
NCT ID
NCT00940719
First Posted
July 15, 2009
Last Updated
August 10, 2010
Sponsor
Maastricht University Medical Center
Collaborators
Orbis Medical Centre
1. Study Identification
Unique Protocol Identification Number
NCT00940719
Brief Title
Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)
Official Title
The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
July 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Orbis Medical Centre
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In patients with Relapsing Remitting Multiple Sclerosis (RRMS), the investigators observed a positive correlation between regulatory T cell (Treg) function and vitamin D status. The present goal is to assess whether Treg function improves on supplementation with vitamin D3.
Detailed Description
In several studies, Multiple Sclerosis (MS) incidence and disease activity has been related with vitamin D status. We observed that RRMS patients who remained relapse free before blood collection had a better vitamin D status than patients who experienced relapses (Smolders et al. Mult Scler 2008;17:1220-1224). Since vitamin D3 is a potent promotor of T cell regulation in vitro (Smolders et al. J Neuroimmunol 2008;194:7-17), we hypothesised that a promotion of Treg function in MS patients might underlie its association with MS disease activity. In a cohort of RRMS patients, we observed a positive correlation of Treg function with vitamin D status (Smolders et al. PLoS ONE 2009;4:e6635). Furthermore, vitamin D status correlated positively with a Th1/Th2-balance which was more directed towards Th2. In the present study, we will assess whether treatment of RRMS patients with vitamin D3 promotes T cell regulation.
In the present study, RRMS patients will be supplemented with vitamin D3, and regulatory T cell tests will be performed before and after supplementation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
Multiple Sclerosis, Regulatory T cell function, Vitamin D, Vitamin D3, 25-hydroxyvitamin D
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D3
Arm Type
Experimental
Arm Description
Patients receive 1dd 500ug vitamin D3 for 3 months
Intervention Type
Dietary Supplement
Intervention Name(s)
vitamin D3
Other Intervention Name(s)
Vigantol Oil (Merck)
Intervention Description
Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
Primary Outcome Measure Information:
Title
T cell regulation
Time Frame
3 months
Secondary Outcome Measure Information:
Title
serum 25-hydroxyvitamin D levels
Time Frame
3 months
Title
calcium metabolism
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Relapsing Remitting MS (Revised MCDonald criteria 2005)
Age > 18 years
Exclusion Criteria:
Progressive MS phenotype
Abnormalities of vitamin D hormonal system other than low dietary intake or limited sun exposure
Intake of drugs that influence vitamin D homeostasis other than corticosteroids
Conditions with in increased susceptibility to hypercalcemia
Alcohol or drug abuse
Pregnancy or the intention to become pregnant within the study period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raymond Hupperts, M.D., Ph.D.
Organizational Affiliation
Orbis Medical Center Sittard, Maastricht Univeristy Medical Center Maastricht
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Joost Smolders, M.D.
Organizational Affiliation
Maastricht University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Orbis Medical Center
City
Sittard
ZIP/Postal Code
6130MD
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
18653736
Citation
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008 Nov;14(9):1220-4. doi: 10.1177/1352458508094399. Epub 2008 Jul 24.
Results Reference
background
PubMed Identifier
18177949
Citation
Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008 Feb;194(1-2):7-17. doi: 10.1016/j.jneuroim.2007.11.014. Epub 2008 Jan 4.
Results Reference
background
PubMed Identifier
19675671
Citation
Smolders J, Thewissen M, Peelen E, Menheere P, Tervaert JW, Damoiseaux J, Hupperts R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009 Aug 13;4(8):e6635. doi: 10.1371/journal.pone.0006635.
Results Reference
background
PubMed Identifier
20211254
Citation
Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):243-6. doi: 10.1016/j.jsbmb.2010.03.001. Epub 2010 Mar 6.
Results Reference
background
PubMed Identifier
21179201
Citation
Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, Damoiseaux J. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010 Dec 13;5(12):e15235. doi: 10.1371/journal.pone.0015235.
Results Reference
derived
Learn more about this trial
Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)
We'll reach out to this number within 24 hrs